On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African Health Products Regulatory Agency for emergency use authorization of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.

If authorized, the vaccine (known as NVX-CoV2373) will be manufactured by and commercialized by SII in South Africa under the brand name Covovax.